Literature DB >> 17891273

Chagas disease in Andean countries.

Felipe Guhl1.   

Abstract

The Andean Countries' Initiative (ACI) for controlling Chagas disease was officially created in 1997 within the framework of the Hipolito Unanue Agreement (UNANUE) between the Ministries of Health of Colombia, Ecuador, Peru, and Venezuela. Its objective was to interrupt transmission via vector and transfusion in the region, taking into account that there are 12.5 million people at risk in the four Andean countries forming the initiative in the area and around 3 million people are infected by Trypanosoma cruzi. The progress of control activities for the vector species present in the Andean sub-region, for different reasons, has been slow and control interventions have still not been installed in all geographical areas occupied by the target species. This has been partly due to lack of knowledge about these vector populations' biological characteristics, and consequent uncertainty about which are the appropriate control measures and strategies to be implemented in the region. The main vector species present important similarities in Venezuela and Colombia and in Ecuador and Northern Peru and they can be approached in a similar way throughout the whole regions, basing approaches on and adapting them to the current strategies being developed in Venezuela during the 1960s which have been progressively adopted in the Southern Cone and Central-American region. Additional measures are needed for keeping endemic areas free from Rhodnius prolixus silvatic populations, widely spread in the Orinoco region in Colombia and Venezuela. Regarding aetiological treatment, it is worth mentioning that (with the exception of Colombia) none of the other countries forming the ACI have registered medicaments available for treating infected young people. There are no suitable follow-up programmes in the sub-region or for treating cases of congenital Chagas disease. An integral and integrated programme encompassing all the aspects including transmission by transfusion which seems to have achieved extremely encouraging results in all countries, are urgently needed.

Entities:  

Mesh:

Year:  2007        PMID: 17891273     DOI: 10.1590/s0074-02762007005000099

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  28 in total

1.  Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods.

Authors:  Juan David Ramírez; Felipe Guhl; Eufrosina Setsu Umezawa; Carlos A Morillo; Fernando Rosas; Jose A Marin-Neto; Silvia Restrepo
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

2.  A highly sensitive rapid diagnostic test for Chagas disease that utilizes a recombinant Trypanosoma cruzi antigen.

Authors:  C A Barfield; R S Barney; C H Crudder; J L Wilmoth; D S Stevens; S Mora-Garcia; M J Yanovsky; B H Weigl; J Yanovsky
Journal:  IEEE Trans Biomed Eng       Date:  2011-03       Impact factor: 4.538

3.  Exploring the molecular complexity of Triatoma dimidiata sialome.

Authors:  Paula Beatriz Santiago; Carla Nunes de Araújo; Sébastien Charneau; Izabela Marques Dourado Bastos; Teresa Cristina F Assumpção; Rayner Myr Lauterjung Queiroz; Yanna Reis Praça; Thuany de Moura Cordeiro; Carlos Henrique Saraiva Garcia; Ionizete Garcia da Silva; Tainá Raiol; Flávia Nader Motta; João Victor de Araújo Oliveira; Marcelo Valle de Sousa; José Marcos C Ribeiro; Jaime Martins de Santana
Journal:  J Proteomics       Date:  2017-12-27       Impact factor: 4.044

4.  Opportunities and challenges in chronic Chagas cardiomyopathy.

Authors:  George A Mensah; Kristin M Burns; Emmanuel K Peprah; Uchechukwu K A Sampson; Michael M Engelgau
Journal:  Glob Heart       Date:  2015-09

5.  Evaluation of spatially targeted strategies to control non-domiciliated Triatoma dimidiata vector of Chagas disease.

Authors:  Corentin Barbu; Eric Dumonteil; Sébastien Gourbière
Journal:  PLoS Negl Trop Dis       Date:  2011-05-17

Review 6.  The unfinished public health agenda of chagas disease in the era of globalization.

Authors:  Carlos Franco-Paredes; Maria Elena Bottazzi; Peter J Hotez
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07

Review 7.  New, improved treatments for Chagas disease: from the R&D pipeline to the patients.

Authors:  Isabela Ribeiro; Ann-Marie Sevcsik; Fabiana Alves; Graciela Diap; Robert Don; Michael O Harhay; Shing Chang; Bernard Pecoul
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07

8.  Do the new triatomine species pose new challenges or strategies for monitoring Chagas disease? An overview from 1979-2021.

Authors:  Jane Costa; Carolina Dale; Cleber Galvão; Carlos Eduardo Almeida; Jean Pierre Dujardin
Journal:  Mem Inst Oswaldo Cruz       Date:  2021-05-31       Impact factor: 2.743

9.  Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.

Authors:  Salomé C Vilchez Larrea; Teemu Haikarainen; Mohit Narwal; Mariana Schlesinger; Harikanth Venkannagari; Mirtha M Flawiá; Silvia H Fernández Villamil; Lari Lehtiö
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

10.  Recombinant Arthrobacter β-1, 3-glucanase as a potential effector molecule for paratransgenic control of Chagas disease.

Authors:  Christo Jose; Nicole Klein; Sarah Wyss; Annabeth Fieck; Ivy Hurwitz; Ravi Durvasula
Journal:  Parasit Vectors       Date:  2013-03-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.